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creativecommons.org/licenses/by-nc-nd/Abstract Background: Chemotherapy is the mainstay treatment for advanced biliary cancer
(ABC). Best supportive care and clinical trials are currently alternative options. The identifi-
cation of a prognostic score that can be widely applied to daily practice has the potential to
better inform clinical management of ABC patients.
Methods: A cohort of 123 ABC patients undergoing first-line chemotherapy was used as an
exploratory cohort to define the prognostic value of laboratory tests routinely performed in
clinical practice. KaplaneMeier analysis was used to investigate the association between the
variables and overall survival (OS). Those variables that were statistically significant at the
multivariate analysis were combined in a multiplex score. Performance of the novel prognostic
score was confirmed in a validation cohort of 60 ABC patients.
Results: Baseline actual neutrophil count, lymphocytes-monocytes ratio, neutrophil-lympho-
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three classes of ABC patients with significantly different OS (high-risk: median OS, 5 months;
intermediate-risk: median OS, 12 months and low-risk: median OS, 22 months; p:<0.001). The
score performed well in the different subtypes of ABC and was independent of stage, perfor-
mance status and chemotherapy regimen. The performance of the A.L.A.N. score was
confirmed in a validation cohort of cholangiocarcinoma patients (high-risk: median OS, 4.3
months; intermediate-risk: median OS 9.3 months, low-risk: median OS 13 months; p:0.005).
Conclusions: The A.L.A.N score can be derived by variables routinely recorded in clinical
practice and can provide prognostic assessment of ABC patients considered for first-line treat-
ment.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Biliary tract cancers are heterogeneous tumour entities
arising from the biliary tree that encompass intrahepatic
cholangiocarcinoma (iCCA), perihilar chol-
angiocarcinoma (pCCA), distal cholangiocarcinoma
(dCCA) and gallbladder carcinoma (GBC) [1]. Although
relatively uncommon in Western countries with roughly
9000 new cases in the United States [2], 2000 new cases
in UK and 4900 new cases in Italy [3] annually, their
incidence is increasing worldwide [4]. Curative-intent
surgical resection can be pursued only in 10e20% of
cases, and recurrence rates remain as high as 40e60%
[5]. The vast majority of patients presents with advanced
disease at diagnosis. Chemotherapy is the mainstay of
treatment for advanced biliary cancers (ABCs) with
median overall survival (OS) hardly exceeding 12
months [6]. It is of paramount importance to properly
select patients to treat those more likely to benefit, while
sparing others from unacceptable toxicities. Hence,
different research efforts have attempted to develop
clinically useful tools aiding patients’ stratification. To
date, several factors have shown to be correlated with
survival of ABC: Eastern Cooperative Oncology Group
(ECOG) performance status (PS), primary tumour
location, disease status and number of metastatic sites
[7e9]. However, in ABC patients fit to receive first-line
chemotherapy, the capability of these models to accu-
rately predict prognosis is limited, making the develop-
ment of biomarkers for patients’ selection still an unmet
need both in daily practice and within clinical trials.
Growing evidence is supporting the involvement of the
immune system in the modulation of response to
chemotherapy [10e12]. ABC is known to arise in the
background of chronic inflammation (e.g. cholecystitis,
hepatobiliary fluke infestation and primary sclerosing
cholangitis) and to be characterised by an enrichment of
inflammatory mediators [13,14], raising the interest
around host immune system and inflammation de-
terminants as predictors of outcome. Interestingly,
several reports suggested that the derived neutrophil/
lymphocyte ratio (NLR) can more precisely predict
prognosis than ECOG PS, showing the latter asinsufficient to reflect the complex biological impact of
this disease [15]. In this view, neutrophil, lymphocyte
and platelet count, their ratios and the dynamic change
of these ratios during chemotherapy, are known to
reflect both systemic inflammation and immune system
fitness and are thus regarded as promising prognostic
factors in ABC [16,17]. More recently, monocytes have
emerged as an important determinant of prognosis in
ABC [18,19], a finding that is also supported by bio-
logical evidence of the role of myeloid-derived suppres-
sive cells in the pathogenesis of cancers [20].
In the present study, we investigated the prognostic
value of clinical factors together with an extensive panel
of immune-inflammatory markers in ABC patients
treated with first-line chemotherapy with the aim of
developing a prognostic model to improve patients’ risk-
stratification in the daily practice.
2. Materials and methods
2.1. Patient selection
Patients with cytohistologically proven unresectable
biliary tract cancer treated with first-line chemotherapy
were retrospectively identified from the Modena Cancer
Centre (exploratory cohort) and the Royal Marsden
Hospital (validation cohort) Biliary Tract Cancer Da-
tabases, after review from the appropriate health
research authorities (HRA). The study protocol con-
formed to the ethical guidelines of the 1975 Declaration
of Helsinki. Data from the Modena cohort were
collected under the protocol 183/2019 that was reviewed
by the Area Vasta Emilia Nord Ethics committee, while
data from the Royal Marsden cohort were collected
under the research protocol CCR4415 that has received
approval from the HRA Yorkshire & The Humber
South Yorkshire Research Ethics Committee.
Patients with mixed hepatocellular-cholangiocellular
carcinoma as well as ampullary carcinoma were
excluded. Patients with signs and/or symptoms sugges-
tive for infectious disease within 2 weeks of starting
treatment were not included in the analysis. Radio-
therapy treatment was not allowed. None of the patients
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ablation) before first-line chemotherapy nor received
ablation and/or surgery of the metastatic sites. Various
chemotherapy regimens were administered as indicated
in the result section. Clinical and laboratory data were
retrieved through electronic medical records review. The
following baseline variables were collected and analysed
before the commencement of first-line chemotherapy:
age, gender, ECOG PS, primary tumour site, disease
status, first-line regimen, hematological and biochemical
parameters including white blood cell count (cell/ml),
haemoglobin (gr/dl), platelet count (cell/ml), bilirubin
(mg/dL), alkaline phosphatase (ALP; IU/L), lactate
dehydrogenase (LDH U/L), alanine aminotransferase
(IU/L), aspartate aminotransferase (AST; IU/L), albu-
min (g/dL), carbohydrate antigen 19-9 (CA 19-9) (U/
mL) and carcinoembryonic antigen (CEA) (ng/ml).2.2. Statistical analysis
The primary end-point was OS calculated from the date
of the first cycle of front-line chemotherapy to the date
of death for any cause or last follow-up visit. Contin-
uous variables were reported as the median and 25e95
percentile, while categorical variables were reported as
absolute and percentage frequencies. Laboratory vari-
ables initially recorded as continuous parameters were
later dichotomised according to usual clinical thresholds
reported in the literature or according to their upper 75
percentile, chosen as worst status. The OS was calcu-
lated using Kaplan-Meier estimators [21]. Statistical
comparisons between curves were performed with the
log-rank test, and the effects were estimated using the
Cox proportional hazard (PH) regression analysis, with
a confidence interval at 95% (95% CI) [22]. The pro-
portionality of hazard was checked graphically with
scaled Schoenfeld residuals [23]. The prognostic per-
formance of each variable on OS was first evaluated by
means of Cox PH univariate model, selecting covariates
with p value <0.20. The final model was developed step
by step in multiple Cox PH regression using the likeli-
hood ratio test. Furthermore, the over-optimism and
calibration of the model was computed over 250 boot-
strap replications by means of Harrell’s methods [24].
For all tests, a two-sided p-value <0.05 was considered
to demonstrate a moderate strength of evidence against
the null hypothesis. This level of probability is helpful
for providing clinically useful advice.3. Results
3.1. Exploratory cohort
Overall, 218 patients with biliary tract cancer were
identified through the Modena Cancer Centre Biliary
Tract Cancer Database search from 1st January 2010 to31st July 2017. One hundred and twenty-three patients
(56%) fulfilled all the above-mentioned criteria and were
therefore included in the analysis. The median age of the
patients was 67 years (range 29e85 years), and 65 (53%)
of them were women. Primary tumour sites of disease
were iCCA (50%), GBC (31%) and eCCA (19%; 12%
pCCA and 7% dCCA). Amongst patients with iCCA,
the prevalence of liver cirrhosis was 8%. One hundred
eight patients (88%) had metastatic disease, while the
remaining 15 (12%) had unresectable locally advanced
disease. One hundred ten (89%) patients received
doublet chemotherapy as first-line treatment and 104
(85%) platinum/gemcitabine combination. Overall, 58%
received cisplatin-gemcitabine, while 42% received other
regimens (which included 15% single-agent chemo-
therapy and 85% other combinations). Disease control
was achieved in 75% of cases with an objective response
rate of 23%. Thirty-six patients (29%) received second-
line chemotherapy. Other baseline clinical and labora-
tory characteristics are summarised in Table 1. As of
data cut-off, 111 patients had died, median OS in the
whole patients’ population was 12 months (95% CI,
7e14 months) and 1-year OS was 52% (Supplementary
Fig. 1A).
3.2. Univariate analysis, multivariate analysis and
prognostic score development
When assessed by univariate analysis, ECOG PS  2,
GBC as primary tumour site, metastatic disease, mon-
ochemotherapy, LDH > upper normal limit, AST > 40
IU/L, ALP 100 IU/L, albumin <3.5 gr/dl, absolute
neutrophil count (ANC) > 8000/ml, lymphocyte/mono-
cyte ratio (LMR) < 2.1, NLR >3, platelet/lymphocyte
ratio  160, CEA > 9.5 ng/ml and CA19-9 >700 U/L
were significantly associated with shorter OS (Table 2).
At multivariate analysis, the following variables
retained statistical significance as poor prognostic fac-
tors: ANC >8000/ml, LMR <2.1, albumin <3.5 gr/dl,
NLR >3, ECOG PS  2, metastatic status and CEA
>9.5 ng/ml (Table 3). On this basis, we depicted a
prognostic model by combining the four immune-
inflammation variables within the A.L.A.N. score
(Actual neutrophil count, lymphocytes-monocytes ratio,
albumin and neutrophil-lymphocytes ratio) and by
assigning weight Z 1 to each of the following:
ANC > 8000/ml, LMR < 2.1, albumin <3.5 gr/dl and
NLR > 3. Accordingly, patients were stratified into
three different risk groups as follows: low-risk group (0
negative prognostic factors), intermediate-risk group
(from 1 to 2 negative prognostic factors) and high-risk
group (from 3 to 4 negative prognostic factors). Glob-
ally, 38 patients were categorised as low-risk, 55 patients
as intermediate-risk and 30 as high-risk. Survival curves
according to the prognostic model are shown in Fig. 1A.
Median OS for low-, intermediate- and high-risk group
was 22 months (95% CI, 14e32 months), 12 months
Table 2
Univariate analysis in the exploratory cohort.
Covariate HR 95% CI p value
Gender, female versus male 0.69 0.47e1.01 0.058
Age, 70 versus < 70 years 1.98 1.29e3.04 0.058
Performance status ECOG, 2 versus 0-1 2.15 1.46e3.15 <0.001
Site, GBC versus CCA 1.68 1.13e2.50 0.011
Disease status, metastatic versus LA 1.71 1.13e2.60 0.011
First-line, doublet versus
monochemotherapy
0.65 0.44e0.96 0.028
Haemoglobin, <12 versus  12 gr/dl 1.30 0.88e1.90 0.187
WBC, > 10.000 versus  10.000 1.20 0.18e1.90 0.377
ANC, >8000 versus  8000 2.40 1.57e3.67 <0.001
NLR, > 3 versus  3 2.76 1.81e4.20 <0.001
LMR, < 2.1 versus  2.1 2.23 1.44e3.47 <0.001
PLR, >160 versus  160 1.52 1.03e2.23 0.034
LDH, >ULN versus  ULN 1.99 1.25e3.17 0.004
Albumin, < 3.5 versus  3.5 1.69 1.11e2.50 0.013
Bilirubin, >1.3 versus  1.3 1.12 0.73e1.72 0.601
ALP, >100 versus  100 IU/l 1.64 1.13e2.40 0.010
AST, >40 versus  40 IU/l 1.60 1.09e2.35 0.017
ALT, >45 versus  45 IU/l 1.10 0.75e1.61 0.625
CEA, >9.5 versus  9.5 ng/dl 2.28 1.46e3.55 <0.001
CA19-9, >700 versus  700 IU/l 2.25 1.48e3.43 <0.001
CCA, cholangiocarcinoma; ANC, absolute neutrophil count; ALP,
alkaline phosphatase; LDH, lactate dehydrogenase; ALT, alanine
aminotransferase; AST, aspartate aminotransferase; CA19-9, carbo-
hydrate antigen 19-9; CEA, carcinoembryonic antigen; ECOG,
Eastern Cooperative Oncology Group; GBC, gallbladder carcinoma;
UNL: upper normal limit; NLR, neutrophil/lymphocyte ratio; LMR,
lymphocyte/monocyte ratio; PLR, platelet/lymphocyte ratio; WBC,
white blood cells; LA, locally advanced.
Table 3
Multivariate analysis in the exploratory cohort.
Covariate HR 95% CI p value
LMR
<2.1 1.60 1.02e3.08 0.045
Albumin g/dl
<3.5 1.62 1.04e2.50 0.031
NLR
>3 1.74 1.03e2.97 0.042
ANC
>8000 2.12 1.27e3.54 0.004
Performance status
ECOG 2 versus 0-1 2.16 1.28e3.64 0.004
Disease status
Metastatic versus LA 2.22 1.30e3.78 0.003
CEA ng/ml
>9.5 2.59 1.55e4.32 <0.001
ECOG, Eastern Cooperative Oncology Group; NLR, neutrophil/
lymphocyte ratio; LMR, lymphocyte/monocyte ratio; ANC, absolute
neutrophil count, CEA, carcinoembryonic antigen; CI, confidence in-
terval; HR, hazards ratio; LA, locally advanced
Variables that resulted statistically significant in the multivariate
analysis are reported. Shrinkage (overfitting) 0.099. c-Harrell Train
0.702 Test 0.692.
Table 1
Patients characteristics in the exploratory cohort (n Z 123).
Variable N (%)
Age, years (median, range) 67 (29e85)
Gender
Female 65 (53%)
Male 58 (47%)
Performance status
ECOG 0-1 101 (82%)
ECOG 2 22 (18%)
Primary tumour site,
iCCA 61 (50%)
pCCA 15 (12%)
dCCA 9 (7%)
GBC 38 (31%)
Disease status
Locally advanced 15 (12%)
Metastatic 108 (88%)
Number of metastatic sites
0 15 (12%)
1 59 (48%)
2 28 (23%)
3 15 (12%)
Metastatic sites
Liver 82 (76%)
Abdominal lymph node (M1) 27 (25%)
Peritoneum 21 (19%)
Lung 15 (14%)
Others 12 (11%)
First-line chemotherapy regimen
Cisplatin/Gemcitabine 71 (58%)
GEMOX 33 (27%)
Others 11 (9%)
Gemcitabine 8 (6%)
Laboratory tests (median, range)
ANC, cells/ml 5504 (1690e36230)
Haemoglobin, gr/dl 12.4 (9.0e16.2)
Platelets, cells/ml 255 (86e1160)
Albumin, gr/dl 37 (21e49)
ALP, IU/L 227 (11e1387)
AST, IU/L 34 (9e1088)
ALT, IU/L 36 (6e721)
Bilirubin, gr/dl 0.75 (0.03e9.6)
CEA, ng/ml 2.6 (0.2e2029)
CA19-9, U/ml 120 (0.6e49454)
iCCA, intrahepatic cholangiocarcinoma; pCCA, perihilar chol-
angiocarcinoma; dCCA, distal cholangiocarcinoma; ANC, absolute
neutrophil count; ALP, alkaline phosphatase; LDH, lactate dehydro-
genase; ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic
antigen; ECOG, Eastern Cooperative Oncology Group; GBC, gall-
bladder carcinoma.
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months), respectively. The difference in survival was
statistically significant between groups (p < 0.001). The
score did not significantly associate with other relevant
prognostic factors such as PS (Chi-square test p: 0.68)
and disease status (Chi-square test p: 0.13). The prog-
nostic performance of the model was maintained
regardless of primary tumour site (Supplementary
Fig. 1B) and chemotherapy regimen (Supplementary
Fig. 1C).3.3. External validation data set
Patients diagnosed with cholangiocarcinoma within the
CCR4415 protocol were identified at the Royal
Fig. 1. A. Overall survival according to the A.L.A.N. score in the exploratory cohort. Patients were classified according to the A.L.A.N.
score in low-risk (0), intermediate-risk (1e2) and high-risk (3e4) groups. Median OS was 22 months in the low-risk, 12 months in the
intermediate-risk and 5 months in the high-risk group. Log-rank p < 0.001. B. Overall survival by the A.L.A.N. score in the validation
cohort. Patients were classified according to the A.L.A.N. score in low-risk (0), intermediate-risk (1e2) and high-risk (3e4) groups.
Median OS was 12.9 (95% CI: 8.7e26.4) months in the low-risk, 9.3 (95%CI: 7.4e14.7) months in the intermediate-risk and 4.3 (95%CI:
2.6e9.2) months in the high-risk group. Log-rank p Z 0.005. OS, overall survival; CI, confidence interval; A.L.A.N., actual neutrophil
count, lymphocytes-monocytes ratio, neutrophil-lymphocytes ratio and albumin.
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to 1st July 2015. Out of 96 patients, 60 with ABC treated
with first-line chemotherapy were eligible for this study
(Table 4). Median age was 64 years, 31 were male and 45
(75%) had metastatic disease. Thirty-three (53%) pa-
tients received combination chemotherapy with cisplatin
and gemcitabine, and 24 (25%) received second-line
treatment. The median OS of the validation cohort was
9.24 months (Supplementary Fig. 1D). At univariate
analysis, the variables included in the A.L.A.N. immu-
noscore were significantly associated to OS when
considered independently (Supplementary Table 1).
When combined in the A.L.A.N score, the population
was classified in three separate groups with significantly
different OS: low-risk group (12.9 median OS, 95% CI
8.7e26.4; NZ 14), intermediate-risk group (9.3 medianTable 4
Patients characteristics in the validation cohort (n Z 60).
Variable N (%)
Age, years (median, range) 64 (54e70)
Gender
Female 31 (52%)
Male 29 (48%)
Performance status
ECOG 0-1 50 (83%)
ECOG 2 10 (17%)
Primary tumour site
iCCA 17 (28%)
pCCA 18 (30%)
dCCA 19 (32%)
Unknown 13 (20%)
Disease status
Locally advanced 15 (25%)
Metastatic 45 (75%)
First-line chemotherapy regimen
Cisplatin/gemcitabine 33 (55%)
Gemcitabine 13 (22%)
Others 14 (23%)
ECOG, Eastern Cooperative Oncology Group; iCCA, intrahepatic
cholangiocarcinoma; pCCA, perihilar cholangiocarcinoma; dCCA,
distal cholangiocarcinoma.OS, 95% CI 7.4e14.7; NZ 33) and high-risk group (4.3
median OS, 95% CI 2.6e9.2; N Z 13) (Fig. 1B). The
score maintained statistical significance at the multi-
variate analysis when stage of disease and PS were
assessed (Table 5).4. Discussion
Herein, we provide initial evidence of a prognostic score
which takes into account markers of inflammation and
immunity, demonstrating a good performance in risk-
stratifying ABC patients treated with first-line chemo-
therapy into three statistically significant different
groups. Of note, the discriminant power of the score was
independent of primary tumour site.
The value of immune-inflammatory markers in can-
cer patients stands on the potential of mirroring the
complex network of cancer-related inflammation within
the tumour microenvironment, an established hallmark
of cancer. Chronic biliary tract inflammation is well-
known to promote cholangiocarcinogenesis as well asTable 5
Multivariate analysis for the validation cohort.
Covariate HR 95% CI p value
A.L.A.N. score,
Low-risk Reference category
Intermediate-risk 2.46 (0.92e6.58) 0.07
High-risk 6.79 (2.22e20.82) 0.001
Age 1.00 0.96e1.03 0.80
Gender
Female versus male 1.08 0.56e2.11 0.82
Performance status
ECOG 2 versus 0-1 1.66 0.64e4.28 0.63
Disease status
Metastatic versus LA 0.81 0.35e1.89 0.63
OS, overall survival; CI, confidence interval; A.L.A.N., actual
neutrophil count, lymphocytes-monocytes ratio, neutrophil-
lymphocytes ratio and albumin; ECOG, Eastern Cooperative
Oncology Group. LA, locally advanced.
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stimulation by mediators acting as potent biliary mito-
gens. Interleukin-6, whose serum levels are elevated in
cholangiocarcinoma, has been shown to contribute via
autocrine and/or paracrine mechanism to growth stim-
ulation of malignant cholangiocytes [25]. The monocyte-
derived cytokine tumour necrosis factor can promote
lymphangiogenesis in ABC via multiple pathways [26].
In addition to tumoural mediators, cellular components
such as neutrophils, monocytes-macrophages and lym-
phocytes are pivotal orchestrators of cancer-promoting
inflammation via extracellular matrix remodelling,
enhancement of cancer cell invasion and metastasis,
angiogenesis, cancer cell proliferation, lymphangio-
genesis and inhibition of the antitumoural immune
surveillance [27]. High tumour-associated neutrophils,
low CD8þT cells and high T regulatory cells have been
reported to be significantly associated with worse OS in
a series of resected ABC [28]. Their value in peripheral
blood is thought to reflect and inform on the balance
between systemic inflammation and immune system in
cancer patients in a reliable and easily accessible way.
Our findings are in keeping with published literature
suggesting NLR as an independent prognostic factor in
patients with both early and advanced biliary cancers
[7,15]. The prognostic significance of NLR relies on the
rise of absolute neutrophil count (a poor prognostic
factor per se) and the decrease in lymphocyte count that
likely reflects an insufficient antitumour immunological
reaction. To our knowledge, this is the first study
showing a prognostic role also for LMR in biliary tract
cancer. A previous meta-analysis showed that pretreat-
ment low LMR was associated with unfavourable OS in
patients with both early-stage and advanced-stage solid
cancers [29] but included gastrointestinal tumours
arising outside the biliary tract. It is difficult to speculate
if the effect on the outcome is related more to the in-
crease in monocyte counts or the depletion of lympho-
cytes. Both events occur in ABC, where the circulating
CD14þ/CD16þ monocytes are thought to be the pre-
cursors of resident macrophages that contribute to
tumourigenesis via paracrine stimuli cancers [30,31].
Nonetheless evidence points to a reduced activation of
lymphocytes with antitumour activity in ABC that
characterises an immunosuppressive milieu [10].
Consistently with previous reports, we confirmed that
low albumin levels (<3.5 gr/dl) were predictive of
shorter OS in patients receiving first-line chemotherapy
in ABC [32]. Hypoalbuminaemia is linked to cancer-
related inflammation and cachexia and has been asso-
ciated with higher mortality rates in several cancer types
[33].
The combination of all these single parameters in a
multiplexed score, such as the one we propose, has the
potential to reflect the various inflammatory/immunity
reactions occurring in cancer patients. Indeed,
conversely to single parameters (i.e. as LNR) theA.L.A.N. score can differentiate three different groups
with clearly separated OS, which allows discussion for
better tailored treatment. The A.L.A.N score can iden-
tify patients with an extremely poor OS (<5 months).
On the contrary, patients in the low- and intermediate-
risk groups are likely to receive more than one line of
treatment, and therefore, discussion of clinical trials as
first-line or second-line choice represent a feasible op-
tion that is unlikely to be limited by a rapid deteriora-
tion of the disease. We acknowledge that our data
support a prognostic assessment of ABC patients, while
more information is needed to understand a predictive
value of the score that could inform chemotherapy
decision.
The retrospective design of our study along with its
relatively small sample size is a limitation to be
acknowledged. Other inflammation markers (i.e. C-
reactive protein) have not been included in the analysis,
given our intent was to propose a score that would be
pragmatically applicable in routine clinical practice;
however, we acknowledge that the incorporation of
other parameters may improve the performance of the
score. In addition, full molecular characterisation of
these tumours has not been performed, and therefore,
we cannot weigh the prognostic value of indicated gene
mutations. Nonetheless, we believe that the A.L.A.N.
score can be widely accessible to oncologists across the
world because it is not associated to additional costs and
provides an advantage over PS alone to prognostically
classify ABC patients undergoing first-line chemo-
therapy, by identifying a limited group of patients with
particularly adverse prognosis.5. Conclusions
In conclusion, while waiting for molecular biomarkers
to enable better risk stratification, our prognostic model
represents a useful tool to add to established clinical
parameters to ameliorate the accuracy of patients’ se-
lection in daily practice. Notably, the better patients’
stratification by inflammation status and immune cell
profile can have interesting therapeutic implications,
especially in the light of latest immunological ap-
proaches and antiinflammatory drugs available.Conflict of interest statement
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